此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

The Effect of Probiotics in Infantile Colic (CSUB0214)

2026年11月5日 更新者:Roberto Berni Canani, MD, PhD、Federico II University

Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Effect of L. Reuteri on Crying and Fussing Time in Infants With Infantile Colic

Academic, independent, non-commercial, multicenter study sponsored by the Department of Translational Medical Sciences (DISMET), University of Naples Federico II. The study evaluates whether daily oral supplementation with L reuteri reduces crying and fussing time more rapidly than an indistinguishable placebo in otherwise healthy infants with Rome IV infantile colic.

研究概览

详细说明

Eligible participants will meet the clinical description for having infant colic. Participants will be assessed for eligibility at the screening visit and must meet all specified inclusion and exclusion criteria. Based on screening examinations, the individual Family Pediatrician (PLS) is solely responsible for determining clinical eligibility and making the final enrollment decision, which will be documented on the Participant Screening and Enrolment Log. The Scientific Coordinator will exclusively monitor aggregate screening logs and enrollment targets across all active sites, without direct involvement in the clinical selection. Fifty infants will be randomized 1:1 to probiotic or placebo. Each participant will complete a 7-day run-in, 21 days of treatment and 7 days of safety follow-up.

研究类型

介入性

注册 (估计的)

50

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Robeto Berni Canani, PhD, MD
  • 电话号码:+390817462680
  • 邮箱:berni@unina.it

学习地点

      • Naples、意大利、80100
        • 招聘中
        • Family pediatricians
        • 接触:
          • Roberto Berni Canani, MD, PhD
          • 电话号码:+390817462680
          • 邮箱:berni@unina.it

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

3周 至 2个月 (孩子)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age 3-12 weeks at screening;
  • gestational age 37+0 to 42+0 weeks;
  • birth weight appropriate or large for gestational age;
  • parent/caregiver/legal guardian older than 18 years;
  • exclusive or predominant breastfeeding (>50%);
  • willingness to maintain feeding pattern and complete diaries and questionnaires;
  • physician-confirmed Rome IV infantile colic, parental report of ≥3 hours of crying/fussing per day on ≥3 days in the prior week, and ≥3 hours in at least one 24-hour period documented in the run-in diary;
  • written informed consent; mother available for scheduled visits; infant otherwise clinically healthy.

Exclusion Criteria:

  • Severe gastroesophageal reflux (as defined in the protocol);
  • failure to thrive;
  • intrauterine growth restriction;
  • hematochezia;
  • significant diarrhea or fever ≥38 °C;
  • congenital heart disease, immunodeficiency, asplenia, malignancy, cystic fibrosis or liver disease;
  • probiotic or systemic/oral antibiotic use in the 7 days before screening or anticipated use during the study;
  • use of treatments for infantile colic; including proton pump inhibitors; in the 7 days before screening or during the study.
  • Infant and mother must not participate concurrently in another interventional clinical study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
有源比较器:Probiotic

Probiotic: L. reuteri total 2 × 10⁸ CFU/day, 5 oral drops once daily for 21 days

5 oral drops once daily for 21 days.

安慰剂比较:Placebo

Placebo: matching oil formulation without L. reuteri, 5 oral drops once daily for 21 days.

5 oral drops once daily for 21 days.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Daily total crying and fussing time at day 7
大体时间:7 days after initiation of intervention

Total infant crying and fussing time, expressed as hours per 24-hour period, recorded daily by parents on baby's day diary

7 days after initiation of intervention

次要结果测量

结果测量
措施说明
大体时间
Change in daily total crying and fussing time from baseline to day 7
大体时间:At Day 0 and at day 7 of intervention

Total infant crying duration and fussing time, expressed as hours per 24-hour period, recorded daily by parents on baby's day diary

At Day 0 and at day 7 of intervention
Change in daily total crying and fussing time from baseline to every day during 21days of treatment
大体时间:During 21 days of treatment

Total infant crying duration and fussing time, expressed as hours per 24-hour period, recorded daily by parents on baby's day diary

During 21 days of treatment
Proportion of responder patients assessed using a parent-completed daily sleep diary (Baby's Day Diary)
大体时间:During the first 21 days of treatment

Proportion of patients responders to the treatment, defined as the number of infants with ≥50% reduction in crying and fussing time, expressed as hours per 24-hour period, recorded daily by parents on baby's day diary

During the first 21 days of treatment
Sleeping time
大体时间:During the first 21 days of treatment

Total infant sleep duration, expressed as hours per 24-hour period, recorded daily by parents on baby's day diary

During the first 21 days of treatment
PedsQL Family Impact Module
大体时间:During 21 days of treatment

Changes in PedsQL Family Impact Module range 0-100 (with higher scores reflecting better functioning) from baseline to Days 7 and 21

During 21 days of treatment
Maternal Edinburgh Postnatal Depression Scale score
大体时间:During 21 days of treatment

Changes in Maternal Edinburgh Postnatal Depression Scale score evaluation Total score range: 0 to 30 (higher score on the Edinburgh Postnatal Depression Scale (EPDS) indicates a greater severity of symptoms) from baseline to Days 7 and 21

During 21 days of treatment
Number of participants experiencing adverse events and serious adverse events.
大体时间:From initiation of the intervention (Day 1) through Day 28.Adverse events, serious adverse events

Number of participants experiencing at least one adverse event (AE) or serious adverse event (SAE) during the study. Events will be recorded and characterized according to type, severity, seriousness, and relationship to the study intervention.

From initiation of the intervention (Day 1) through Day 28.Adverse events, serious adverse events
Body temperature
大体时间:At day 0 and 21

body temperature (°C)

At day 0 and 21
Heart rate
大体时间:At day 0 and 21

heart rate (BPM)

At day 0 and 21
Respiratory rate
大体时间:At day 0 and 21

Respiratory rate/minute

At day 0 and 21
Blood pressure
大体时间:At day 0 and 21

blood pressure (mmHg)

At day 0 and 21
Height
大体时间:At day 0 and 21

Height in cm

At day 0 and 21
Weight
大体时间:At day 0 and 21

Weight in Kg

At day 0 and 21

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年9月23日

初级完成 (估计的)

2027年7月1日

研究完成 (估计的)

2027年9月1日

研究注册日期

首次提交

2026年9月24日

首先提交符合 QC 标准的

2026年10月23日

首次发布 (实际的)

2026年10月26日

研究记录更新

最后更新发布 (实际的)

2026年11月9日

上次提交的符合 QC 标准的更新

2026年11月5日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • 204/26

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅